Canaccord Genuity analyst Dewey Steadman maintained a Hold rating on Lipocine (NASDAQ: LPCN) yesterday and set a price target of $1.50. The company’s shares opened today at $1.06, close to its 52-week low of $1.03.
According to TipRanks.com, Steadman ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -6.4% and a 37.1% success rate. Steadman covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals Inc, Pacira Pharmaceuticals, and Cardiome Pharma Corp.
Lipocine has an analyst consensus of Moderate Buy, with a price target consensus of $5.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.33 and a one-year low of $1.03. Currently, Lipocine has an average volume of 488.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Lipocine, Inc. engages in the research and development of treatment for use in men’s and women’s health through proprietary drug delivery technologies. It focuses on oral testosterone replacement therapy and preterm birth prevention. The company was founded on July 24, 2013 and is headquartered in Salt Lake City, UT.
Read More on LPCN:
